These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1597239)
1. Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer. Izembart M; Chavaudra J; Aubert B; Vallée G Eur J Nucl Med; 1992; 19(4):243-7. PubMed ID: 1597239 [TBL] [Abstract][Full Text] [Related]
2. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. Corrêa NL; de Sá LV; de Mello RC Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670 [TBL] [Abstract][Full Text] [Related]
3. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Lassmann M; Reiners C; Luster M Endocr Relat Cancer; 2010 Sep; 17(3):R161-72. PubMed ID: 20448022 [TBL] [Abstract][Full Text] [Related]
4. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Maxon HR; Thomas SR; Samaratunga RC Thyroid; 1997 Apr; 7(2):183-7. PubMed ID: 9133681 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. Garsi JP; Schlumberger M; Rubino C; Ricard M; Labbé M; Ceccarelli C; Schvartz C; Henri-Amar M; Bardet S; de Vathaire F J Nucl Med; 2008 May; 49(5):845-52. PubMed ID: 18413399 [TBL] [Abstract][Full Text] [Related]
6. Initial radioiodine administration: when to use it and how to select the dose. Esposito G Endocrinol Metab Clin North Am; 2014 Jun; 43(2):385-400. PubMed ID: 24891168 [TBL] [Abstract][Full Text] [Related]
8. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499 [TBL] [Abstract][Full Text] [Related]
9. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Vini L; Hyer S; Al-Saadi A; Pratt B; Harmer C Postgrad Med J; 2002 Feb; 78(916):92-3. PubMed ID: 11807191 [TBL] [Abstract][Full Text] [Related]
10. Radioiodine in the treatment of thyroid cancer. Van Nostrand D; Wartofsky L Endocrinol Metab Clin North Am; 2007 Sep; 36(3):807-22, vii-viii. PubMed ID: 17673129 [TBL] [Abstract][Full Text] [Related]
11. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041 [TBL] [Abstract][Full Text] [Related]
12. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide. Stabin MG J Nucl Med; 1993 Apr; 34(4):695-6. PubMed ID: 8455090 [TBL] [Abstract][Full Text] [Related]
13. Ovarian function after radioiodine therapy in patients with thyroid cancer. Souza Rosário PW; Alvarenga Fagundes T; Villas-Boas Fagundes AS; Barroso AL; Lamego Rezende L; Lanza Padrão E; Guimarães VC; Horta AC; Franco M; Purisch S Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):331-3. PubMed ID: 15977100 [TBL] [Abstract][Full Text] [Related]
14. A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods. Yama N; Sakata K; Hyodoh H; Tamakawa M; Hareyama M Ann Nucl Med; 2012 Jun; 26(5):390-6. PubMed ID: 22382609 [TBL] [Abstract][Full Text] [Related]
15. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014 [TBL] [Abstract][Full Text] [Related]
16. Blood radioiodine concentration and blood radiation dosage during I131 therapy for metastatic thyroid carcinoma. SEIDLIN SM; YALOW AA; SIEGEL E J Clin Endocrinol Metab; 1952 May; 12(9):1197-1204. PubMed ID: 12981154 [No Abstract] [Full Text] [Related]
17. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Logue JP; Tsang RW; Brierley JD; Simpson WJ Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407 [TBL] [Abstract][Full Text] [Related]
18. I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal. Hong CM; Kim CY; Son SH; Jung JH; Lee CH; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC Ann Nucl Med; 2017 Oct; 31(8):582-589. PubMed ID: 28677070 [TBL] [Abstract][Full Text] [Related]
19. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect. Yap BK; Murby B J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114 [TBL] [Abstract][Full Text] [Related]